Compared with the KLF15 KO mice, both contractile dysfunction (EF and FS) and cardiac hypertrophy (heart/body weight ratio, heart size, myocyte area and mRNA level of ANP, BNP) were improved in SB265610-treated KLF15 mice (Figures 6A–E,J). Here, KLF15 is linked to cardiac hypertrophy.